Abstract: Objective To evaluate the effects of growth hormone(GH) treatment in idiopathic short status (ISS) children with baseline height ≤ -2 SD on near-adult height(NAH) outcomes.Methods ISS children were included in the current analyses if they had a baseline height ≤ -2 SD and were treated by GH and had been discontinued and attained adult height or NAH. The main outcome measures included near-adult height(NAH)standard deviation scores-target HtSDS in response to GH treatment(△HtSDS=NAHtSDS-T HtSDS), and analysis of correlation with △HtSDS.Results A total of 176 cases of ISS into the group, 106 males and 70 females. Mean chronological age at baseline of male and female were (12.9±2.12)years and (12.1±1.72)years, bone age were (9.5 ±2.53) years and (10.1 ±2.16) years, respectively. The current average ages were 16.74 years and 16.56 years. The follow-up period was 0.27-8.80 years. Mean HtSDS baseline to NAH male:-3.31 to -1.98 and female:-2.86 to -1.39. There were significant difference between baseline to NAH of HtSDS, both male and female were P=0.000. Analysis of non-inferiority test showed that male NAHtSDS were shorter than target HtSDS, while female were not shorter than target HtSDS. Percentages of patients reaching near-adult height>-2SD were male55.7% (59/106),female 71.4% (50/70). Baseline HtSDS, sex and duration of treatment were significantly correlated with △ HtSDS, P values were 0.005, 0.000, 0.027, when analyzed by multiple linear regression.Conclusion Despite a relatively advanced children age, the majority of GH-treated patients in this study attained mean near-adult HtSDS within the normal range(HtSDS>-2SD). Female, higher baseline HtSDS, longer duration of GH treatment would likely have resulted in greater adult height achieved in ISS children.

Key words: idiopathic short status (ISS), growth hormone (GH), near-adult height (NAH), target height (TH), height standard deviation scores (HtSDS)